Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net (loss) income	$ (1,118.6)	$ (100.2)	$ 243.1
Noncash items:
Depreciation	40.8	36.0	31.8
Amortization	82.3	99.6	106.0
Allowance for credit losses	17.9	7.1	4.8
Stock-based compensation expense	35.3	30.7	30.5
Loss (gain) on equity investments, net	0.4	(3.6)	0.0
Loss (gain) on sale of property, plant and equipment	2.8	(5.4)	(1.9)
Gain on sale of KaVo treatment unit and instrument business	0.0	0.0	(8.9)
Restructuring charges	0.0	1.3	4.7
Goodwill and intangible asset impairments	1,153.8	258.3	0.0
Fixed assets impairments and other charges	17.1	0.2	6.4
Fair value adjustment of acquisition-related inventory	0.0	0.0	9.5
Non-cash operating lease costs	31.4	27.0	24.3
Inducement expense related to exchange of convertible notes	0.0	28.5	0.0
Amortization of debt discount and issuance costs	4.9	4.6	4.1
Deferred income taxes	(29.0)	(37.0)	(29.0)
Change in trade accounts receivable	10.0	(17.0)	(71.0)
Change in inventories	3.6	35.1	(39.9)
Change in trade accounts payable	(1.2)	(46.3)	44.5
Change in prepaid expenses and other assets	(6.7)	3.3	(11.7)
Change in accrued expenses and other liabilities	134.5	(12.0)	(133.0)
Change in operating lease liabilities	(42.8)	(34.5)	(31.6)
Net cash provided by operating activities	336.5	275.7	182.7
Cash flows from investing activities:
Payments for additions to property, plant and equipment	(33.8)	(58.2)	(75.7)
Purchases of investments held in rabbi trust	(32.8)	0.0	0.0
Proceeds from sale of investments held in rabbi trust	9.3	0.0	0.0
Proceeds from sales of property, plant and equipment	0.1	6.1	3.3
Proceeds from sale of equity investment	0.4	10.7	0.0
Acquisitions, net of cash acquired	0.0	0.0	(696.2)
Proceeds from sale of KaVo treatment unit and instrument business, net	0.0	0.0	73.9
Proceeds from the settlement of derivative financial instruments	2.5	1.6	56.0
All other investing activities, net	(0.3)	(22.6)	(18.6)
Net cash used in investing activities	(54.6)	(62.4)	(657.3)
Cash flows from financing activities:
Proceeds from stock option exercises	2.4	11.3	21.8
Tax withholding payment related to net settlement of equity awards	(5.3)	(7.9)	(9.1)
Proceeds from issuance of convertible notes due 2028	0.0	500.2	0.0
Principal paid related to exchange of convertible notes due 2025	0.0	(401.2)	0.0
Proceeds from borrowings	0.0	323.5	0.3
Repayment of borrowings	(100.0)	(288.8)	(0.5)
Proceeds from revolving line of credit	0.0	0.0	124.0
Repayment of revolving line of credit	0.0	0.0	(124.0)
All other financing activities	(0.8)	0.1	0.0
Net cash (used in) provided by financing activities	(103.7)	118.9	12.5
Effect of exchange rate changes on cash and cash equivalents	(49.1)	0.9	(4.6)
Net change in cash and cash equivalents	129.1	333.1	(466.7)
Beginning balance of cash and cash equivalents	940.0	606.9	1,073.6
Ending balance of cash and cash equivalents	1,069.1	940.0	606.9
Supplemental data:
Cash paid for interest	54.7	63.2	38.4
Cash paid for taxes	32.9	98.6	119.2
ROU assets obtained in exchange for operating lease obligations	54.8	22.1	36.0
Convertible senior notes due 2028 (the “2028 Convertible Notes”)
Cash flows from financing activities:
Debt issuance costs	0.0	(13.8)	0.0
Other Borrowings
Cash flows from financing activities:
Debt issuance costs	$ 0.0	$ (4.5)	$ 0.0